Anesthesia and Circulating Tumor Cells in Breast Cancer

• Status: Completed
• Trial end date: 2018-04-01
• Target enrollment: 0
• Participant gender: Female

Summary

Serious concern about the role of anesthesia in tumor recurrence has considerably risen over years, but the lack of surrogate markers for tumor spreading made trials addressing this issue difficult to realize. In breast cancer patients CTC positivity has been recently recognized as an independent prognostic factor. In this respect, we postulated that in a first step changes in the number of CTC after general anesthesia would help to determine the effect of anesthesia on this tumor marker.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Zurich
• Treatments: Anesthetics; Propofol; Sevoflurane

Criteria

Inclusion criteria: > Female

• Age 18 to 85

• ASA I-III

• Primary breast cancer (TNM stage = T1-3, N0-2, M0)

• Primary surgery

• Written informed consent

Exclusion criteria:

• Metastatic breast cancer

• Other than primary surgery (recurrence, reconstruction)

• Pre-operative chemotherapy or radiotherapy

• Auto-immune disease, HIV, other active cancer, age>85, ASA IV or V

• Concomitant regional anesthesia

• Chronic opioids medication

• Any systemic immunosuppressive therapy

• Known hypersensitivity or suspected allergy to propofol, soya or egg proteins

• Known hypersensitivity to volatile anesthetics (malignant hyperthermia)

• Pregnancy

• Breast feeding

• Non German-speaking patients

• Enrollment in any other clinical trial during the course of this trial, 30 days prior to its beginning or 30 days after its completion